Eldelumab [Anti-IP-10] induction therapy for ulcerative colitis: A randomised, placebo-controlled, phase 2b study

William J. Sandborn, Jean Frédéric Colombel, Subrata Ghosh, Bruce E. Sands, Gerald Dryden, Xavier Hébuterne, Rupert W. Leong, Brian Bressler, Thomas A. Ullman, Peter L. Lakatos, Walter Reinisch, Li An Xu, Allison Luo

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Background and Aims: Interferon-γ-inducible protein-10 [IP-10] mediates immune cell trafficking from the circulation to the inflamed colon and decreases gut epithelial cell survival. IP-10 expression is increased in patients with ulcerative colitis [UC]. We report efficacy and safety results from a dose-ranging induction study of eldelumab, a fully human monoclonal antibody to IP-10, in moderately to severely active UC. Methods: A total of 252 adults with UC [Mayo score ≥ 6 and endoscopic subscore ≥ 2] were randomised 1:1:1 to placebo or eldelumab 15 or 25 mg/kg administered intravenously on Days 1 and 8 and every other week thereafter. The primary endpoint was clinical remission [Mayo score ≤ 2; no individual subscale score > 1] at Week 11. Key secondary endpoints included Mayo score clinical response and mucosal healing at Week 11. Results: Neither eldelumab 15 or 25 mg/kg resulted in significant increases vs placebo in the proportion of patients achieving Week 11 clinical remission. Remission and response rates were 17.6% and 47.1% with eldelumab 25 mg/kg, 13.1% and 44.0% with eldelumab 15 mg/kg, and 9.6% and 31.3% with placebo. Clinical remission and response rates were higher in anti-tumour necrosis factor [TNF]-naïve patients treated with eldelumab compared with placebo. Eldelumab treatment was well tolerated and no immunogenicity was observed. Conclusions: The primary endpoint was not achieved with induction treatment with eldelumab 15 or 25 mg/kg in patients with UC. Trends towards clinical remission and response were observed in the overall population and were more pronounced in anti-TNF naïve patients. Eldelumab safety signals were consistent with those reported previously [ClinicalTrials.gov number, NCT01294410].

Original languageEnglish (US)
Pages (from-to)418-428
Number of pages11
JournalJournal of Crohn's and Colitis
Volume10
Issue number4
DOIs
StatePublished - Apr 1 2016
Externally publishedYes

Fingerprint

Ulcerative Colitis
Placebos
Proteins
Tumor Necrosis Factor-alpha
Chemokine CXCL10
Therapeutics
Safety
Cell Survival
Colon
Epithelial Cells
Monoclonal Antibodies
Population

Keywords

  • Inflammatory bowel diseases
  • Ulcerative colitis

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Sandborn, W. J., Colombel, J. F., Ghosh, S., Sands, B. E., Dryden, G., Hébuterne, X., ... Luo, A. (2016). Eldelumab [Anti-IP-10] induction therapy for ulcerative colitis: A randomised, placebo-controlled, phase 2b study. Journal of Crohn's and Colitis, 10(4), 418-428. https://doi.org/10.1093/ecco-jcc/jjv224

Eldelumab [Anti-IP-10] induction therapy for ulcerative colitis : A randomised, placebo-controlled, phase 2b study. / Sandborn, William J.; Colombel, Jean Frédéric; Ghosh, Subrata; Sands, Bruce E.; Dryden, Gerald; Hébuterne, Xavier; Leong, Rupert W.; Bressler, Brian; Ullman, Thomas A.; Lakatos, Peter L.; Reinisch, Walter; Xu, Li An; Luo, Allison.

In: Journal of Crohn's and Colitis, Vol. 10, No. 4, 01.04.2016, p. 418-428.

Research output: Contribution to journalArticle

Sandborn, WJ, Colombel, JF, Ghosh, S, Sands, BE, Dryden, G, Hébuterne, X, Leong, RW, Bressler, B, Ullman, TA, Lakatos, PL, Reinisch, W, Xu, LA & Luo, A 2016, 'Eldelumab [Anti-IP-10] induction therapy for ulcerative colitis: A randomised, placebo-controlled, phase 2b study', Journal of Crohn's and Colitis, vol. 10, no. 4, pp. 418-428. https://doi.org/10.1093/ecco-jcc/jjv224
Sandborn, William J. ; Colombel, Jean Frédéric ; Ghosh, Subrata ; Sands, Bruce E. ; Dryden, Gerald ; Hébuterne, Xavier ; Leong, Rupert W. ; Bressler, Brian ; Ullman, Thomas A. ; Lakatos, Peter L. ; Reinisch, Walter ; Xu, Li An ; Luo, Allison. / Eldelumab [Anti-IP-10] induction therapy for ulcerative colitis : A randomised, placebo-controlled, phase 2b study. In: Journal of Crohn's and Colitis. 2016 ; Vol. 10, No. 4. pp. 418-428.
@article{90436055d65940b1afa4ebb7b5427137,
title = "Eldelumab [Anti-IP-10] induction therapy for ulcerative colitis: A randomised, placebo-controlled, phase 2b study",
abstract = "Background and Aims: Interferon-γ-inducible protein-10 [IP-10] mediates immune cell trafficking from the circulation to the inflamed colon and decreases gut epithelial cell survival. IP-10 expression is increased in patients with ulcerative colitis [UC]. We report efficacy and safety results from a dose-ranging induction study of eldelumab, a fully human monoclonal antibody to IP-10, in moderately to severely active UC. Methods: A total of 252 adults with UC [Mayo score ≥ 6 and endoscopic subscore ≥ 2] were randomised 1:1:1 to placebo or eldelumab 15 or 25 mg/kg administered intravenously on Days 1 and 8 and every other week thereafter. The primary endpoint was clinical remission [Mayo score ≤ 2; no individual subscale score > 1] at Week 11. Key secondary endpoints included Mayo score clinical response and mucosal healing at Week 11. Results: Neither eldelumab 15 or 25 mg/kg resulted in significant increases vs placebo in the proportion of patients achieving Week 11 clinical remission. Remission and response rates were 17.6{\%} and 47.1{\%} with eldelumab 25 mg/kg, 13.1{\%} and 44.0{\%} with eldelumab 15 mg/kg, and 9.6{\%} and 31.3{\%} with placebo. Clinical remission and response rates were higher in anti-tumour necrosis factor [TNF]-na{\"i}ve patients treated with eldelumab compared with placebo. Eldelumab treatment was well tolerated and no immunogenicity was observed. Conclusions: The primary endpoint was not achieved with induction treatment with eldelumab 15 or 25 mg/kg in patients with UC. Trends towards clinical remission and response were observed in the overall population and were more pronounced in anti-TNF na{\"i}ve patients. Eldelumab safety signals were consistent with those reported previously [ClinicalTrials.gov number, NCT01294410].",
keywords = "Inflammatory bowel diseases, Ulcerative colitis",
author = "Sandborn, {William J.} and Colombel, {Jean Fr{\'e}d{\'e}ric} and Subrata Ghosh and Sands, {Bruce E.} and Gerald Dryden and Xavier H{\'e}buterne and Leong, {Rupert W.} and Brian Bressler and Ullman, {Thomas A.} and Lakatos, {Peter L.} and Walter Reinisch and Xu, {Li An} and Allison Luo",
year = "2016",
month = "4",
day = "1",
doi = "10.1093/ecco-jcc/jjv224",
language = "English (US)",
volume = "10",
pages = "418--428",
journal = "Journal of Crohn's and Colitis",
issn = "1873-9946",
publisher = "Elsevier",
number = "4",

}

TY - JOUR

T1 - Eldelumab [Anti-IP-10] induction therapy for ulcerative colitis

T2 - A randomised, placebo-controlled, phase 2b study

AU - Sandborn, William J.

AU - Colombel, Jean Frédéric

AU - Ghosh, Subrata

AU - Sands, Bruce E.

AU - Dryden, Gerald

AU - Hébuterne, Xavier

AU - Leong, Rupert W.

AU - Bressler, Brian

AU - Ullman, Thomas A.

AU - Lakatos, Peter L.

AU - Reinisch, Walter

AU - Xu, Li An

AU - Luo, Allison

PY - 2016/4/1

Y1 - 2016/4/1

N2 - Background and Aims: Interferon-γ-inducible protein-10 [IP-10] mediates immune cell trafficking from the circulation to the inflamed colon and decreases gut epithelial cell survival. IP-10 expression is increased in patients with ulcerative colitis [UC]. We report efficacy and safety results from a dose-ranging induction study of eldelumab, a fully human monoclonal antibody to IP-10, in moderately to severely active UC. Methods: A total of 252 adults with UC [Mayo score ≥ 6 and endoscopic subscore ≥ 2] were randomised 1:1:1 to placebo or eldelumab 15 or 25 mg/kg administered intravenously on Days 1 and 8 and every other week thereafter. The primary endpoint was clinical remission [Mayo score ≤ 2; no individual subscale score > 1] at Week 11. Key secondary endpoints included Mayo score clinical response and mucosal healing at Week 11. Results: Neither eldelumab 15 or 25 mg/kg resulted in significant increases vs placebo in the proportion of patients achieving Week 11 clinical remission. Remission and response rates were 17.6% and 47.1% with eldelumab 25 mg/kg, 13.1% and 44.0% with eldelumab 15 mg/kg, and 9.6% and 31.3% with placebo. Clinical remission and response rates were higher in anti-tumour necrosis factor [TNF]-naïve patients treated with eldelumab compared with placebo. Eldelumab treatment was well tolerated and no immunogenicity was observed. Conclusions: The primary endpoint was not achieved with induction treatment with eldelumab 15 or 25 mg/kg in patients with UC. Trends towards clinical remission and response were observed in the overall population and were more pronounced in anti-TNF naïve patients. Eldelumab safety signals were consistent with those reported previously [ClinicalTrials.gov number, NCT01294410].

AB - Background and Aims: Interferon-γ-inducible protein-10 [IP-10] mediates immune cell trafficking from the circulation to the inflamed colon and decreases gut epithelial cell survival. IP-10 expression is increased in patients with ulcerative colitis [UC]. We report efficacy and safety results from a dose-ranging induction study of eldelumab, a fully human monoclonal antibody to IP-10, in moderately to severely active UC. Methods: A total of 252 adults with UC [Mayo score ≥ 6 and endoscopic subscore ≥ 2] were randomised 1:1:1 to placebo or eldelumab 15 or 25 mg/kg administered intravenously on Days 1 and 8 and every other week thereafter. The primary endpoint was clinical remission [Mayo score ≤ 2; no individual subscale score > 1] at Week 11. Key secondary endpoints included Mayo score clinical response and mucosal healing at Week 11. Results: Neither eldelumab 15 or 25 mg/kg resulted in significant increases vs placebo in the proportion of patients achieving Week 11 clinical remission. Remission and response rates were 17.6% and 47.1% with eldelumab 25 mg/kg, 13.1% and 44.0% with eldelumab 15 mg/kg, and 9.6% and 31.3% with placebo. Clinical remission and response rates were higher in anti-tumour necrosis factor [TNF]-naïve patients treated with eldelumab compared with placebo. Eldelumab treatment was well tolerated and no immunogenicity was observed. Conclusions: The primary endpoint was not achieved with induction treatment with eldelumab 15 or 25 mg/kg in patients with UC. Trends towards clinical remission and response were observed in the overall population and were more pronounced in anti-TNF naïve patients. Eldelumab safety signals were consistent with those reported previously [ClinicalTrials.gov number, NCT01294410].

KW - Inflammatory bowel diseases

KW - Ulcerative colitis

UR - http://www.scopus.com/inward/record.url?scp=84966378462&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84966378462&partnerID=8YFLogxK

U2 - 10.1093/ecco-jcc/jjv224

DO - 10.1093/ecco-jcc/jjv224

M3 - Article

C2 - 26721935

AN - SCOPUS:84966378462

VL - 10

SP - 418

EP - 428

JO - Journal of Crohn's and Colitis

JF - Journal of Crohn's and Colitis

SN - 1873-9946

IS - 4

ER -